cyrilzakka/clinical-trials huggingface dataset:
Empowering Patients On Choices for Renal Replacement Therapy (Aim 3) (EPOCH-RRT)

Empowering Patients On Choices for Renal Replacement Therapy (EPOCH-RRT) study seeks to identify factors that matter the most to patients with kidney disease and study how they are impacted by different types of dialysis. The inclusion of patients, caregivers, and patient advocacy organizations as research partners will assure that the study addresses questions of greatest relevance to patients facing the need for dialysis.

For Aim 3, the investigators are going to compare measures related to the decision-making process between patients receiving and not receiving a decision aid focusing on Peritoneal Dialysis and Hemodialysis.


Eligibility Criteria:
Inclusion Criteria:

* 18 years and older
* Speaks English
* Has access to the internet

Exclusion Criteria:
The Efficacy of Clinical Pilates Exercises on Individuals With Lumbar Disc Herniation

The aim of the study is to determine the effects of clinical Pilates Exercises on the level of pain, functional status, flexibility, static and dynamic endurance of the truncus muscles and quality of life in patients with lumbar disc herniation.


Eligibility Criteria:
Inclusion Criteria:

* Individuals, between the ages of 30-60,
* Have been diagnosed according to Magnetic Resonance Imaging results, in one or several of the levels of L3-L4 / L4-L5 / L5-S1 in the case of Bulging and Protuberance lumbar disc hernia,
* At least 6 weeks with back and leg pain,
* Those who will be able to participate in the exercise program regularly,
* Those who are not included in the physiotherapy program in the last 6 months,,
* With mental, auditory and visual problems that will prevent communication will be included in the study.

Exclusion Criteria:

* Individuals, with spinal stenosis,
* Having previously described lumbar spine surgery,
* Having severe neurological deficits,
* Having primary or metastatic spinal malignancy,
* Having vascular problem at a later stage in the lower extremity,
* Diagnosed with osteoporosis,
* Those who are pregnant,
* Having uncontrolled hypertension,
* With anger-dependent anguish will not be included in the study.
Acupuncture Combined With Yanqing Zhitong Ointment Acupoint Application in Chronic Non-specific Low Back Pain

Carry out a randomized controlled double-blind study, the acupuncture combined with placebo application group was compared with the acupuncture combined with Yanqing Zhitong ointment acupoint application group, 86 patients with chronic non-specific low back pain were included.

Treatment group(acupuncture combined with Yanqing Zhitong ointment acupoint sticking) Acupoints for manual acupuncture:Weizhong(BL40), Shenshu(BL23) ,Dachangshu(BL25) ,Geshu(BL17) ,Kunlun(BL60) ,Ashi point Acupoints for sticking:According to the location of pain, we select acupuncture points along the meridian

Controal group(acupuncture combined with placebo application) Interventions are same as Treatment Group.

Both groups were treated 3 times a week for 4 weeks.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnostic of non-specific low back pain
2. Aage from 18 to 65
3. Last for at least 12 weeks
4. VAS between 4 and 7
5. No other treatment in the past 3 months
6. Patients with no partial skin damage
7. No other relevant treatment methods
8. Sign informed consent and informed consent

Exclusion Criteria:

1. Pregnant women
2. Suffer from diabetes
3. With skin ulcers or contusion wounds
4. Past history of severe allergy to transdermal preparations
5. Complicated with serious diseases
Anti Infective Agents Impact in COVID-19 Pneumonia

During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone.

Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.


Eligibility Criteria:
Inclusion Criteria:

* aged over 18 years old
* hospitalized for a COVID-19 pneumonia documented by PCR or lung tomodensitometry,
* admitted outside an intensive care unit, in a medicine ward

Exclusion Criteria:

* patient opposed to data collected, or who could not consent because of a serious presentation of the pneumonia
Non Pharmacological Treatment in Alzheimer's Disease and Associated Disorders

The STIM-EHPAD study (for stimulation in nursing home) aims to evaluate the short and medium term effectiveness of staff education as a non-pharmacological intervention to manage apathy in older people with a diagnosis of dementia.

* Primary efficacy criteria: Apathy Inventory clinician score changes
* Secondary efficacy criteria: Apathy Inventory patient and caregiver version changes, Observation scale changes, frequency and severity of the other BPSD using the NPI, qualitative analysis of the nursing home staff behavioural changes


Eligibility Criteria:
Inclusion Criteria:

* Patients older than 65 years
* A diagnosis of dementia according to the ICD 10 criteria
* MMSE score ≤ 24
* Presenting the diagnostic criteria of apathy (cf page ??)
* An Apathy Inventory clinician total score \>3 (with at least a score higher than 1 at one of the 3 dimensions; lack of initiative, lack of interest, emotional blunting)

Exclusion Criteria:

* Patients more than 65 years
* MMSE score \> 24
Effects of Mindfulness-based Interventions on Improving Teacher Wellbeing and Teaching Outcomes: A Multi-site, Mixed-methods Randomized Controlled Study

This study aims to evaluate the effectiveness of MBCT-L among Chinese teachers on their mental well-being and teaching outcomes and explore the mechanisms of how mindfulness practice brings these benefits. The study is a multi-site, mixed-methods randomized controlled trial including 160 teachers.


Eligibility Criteria:
Inclusion Criteria:

1. Teachers aged 21-65 years;
2. Teachers currently working in a school; and
3. Teachers willing to commit time for the 8-week course.

Exclusion Criteria:

1. Teachers previously joined a related group mindfulness-based intervention, such as mindfulness-based cognitive therapy (MBCT), mindfulness-based stress reduction (MBSR), Mindfulness - Finding Peace in a Frantic World (FPFW); or
2. Teachers who are mentally unstable or having active suicidal risk.
Obstetrical Analgesia in the Estaing Hospital Maternity. A Prospective Database to Study the Determinants of Labor Pain and the Resulting Maternal Non Satisfaction.

There is a trend to offer personalized care in many medical domains. In the field of labor pain, it appears that maternal satisfaction about care is multifactorial, and that labor pain is only one of its determinants, competing with psychological and sociological factors. Furthermore, labor pain is also multifactorial, depending on predisposition to pain, the way analgesia is conducted, and other environmental factors. We wish to develop predicting models of maternal satisfaction, in order to offer in the future a better tailored analgesia.

The observation shall be conducted at 3 major points of measurement throughout labor:

1. Pre-, i.e. at the systematic visit for anesthesia, during the 3rd trimester of pregnancy. The collected variables will be: demographic, morphometric, socioeconomic, psychometric. The latter shall consist in a short questionnaire-based assessment by: Hospital Anxiety and Depression Scale, 5-points Mental Health Inventory, Life Orientation Scale. As soon as it will be validated, a Pain Sensitivity Questionnaire shall be added.
2. Intra-, i.e. clinical data from the anesthesia file: conduction of epidural analgesia, labor pain, drug consumption, obstetrical outcomes.
3. Post-, i.e. maternal satisfaction assessed by a set of seven 11-point numerical rating scales at day2 post childbirth, along with a written short qualitative assessment.

Different multivariable statistical models shall be used to identify the patients profiles and the possible determinants of satisfaction: descriptive (factorial analyses) and inferential (GLM or longitudinal).

Eligibility Criteria:
Inclusion Criteria:

* Any parturient coming for her regular pre-partum anesthesia visit at the Estaing Hospital Maternity

Exclusion Criteria:

* Refusal of epidural analgesia at the time of the visit.
* Participation refusal.
* Inability to answer the pre- or post-partum questionnaires.
* Any medical condition considered as a relevant exclusion criterion by the investigator.
Impact of Inspiratory Muscle Training on Daily Physical Activity (INAF)

The impact of the reduction of daily physical activity (DPA) in patients with COPD (chronic obstructive pulmonary disease) is a highly studied area, due to its impact on the quality of life and the clinical evolution of the disease . This fact has multifactorial components: its function is naturally diminished with time, and its effects on the loss of physical condition (decondition). However, dynamic hyperinflation and respiratory muscular dysfunction, especially in patients with more symptomatology, have been identified as those that have the most relevant factors that impact on daily physical activity Due to the detrimental effects of the pulmonary hyperinflation, the diaphragm is flatter and shorter, being in a position of mechanical disadvantage. This contributes to a reduced effort capacity and increase in the dyspnea of patients during daily activities.

Resistance training improves their exercise capacity and reduces dyspnea, however it does not improve inspiratory muscle strength. It is for this reason, that specific training of the inspiratory muscles, offers special interest in patients with decreased inspiratory muscle strength and pulmonary hyperinflation.


Eligibility Criteria:
Inclusion Criteria:

* To be eligible for the respiratory rehabilitation programme participants must have stable COPD (at least 4 weeks), inspiratory muscle weakness (PImax \<70%) and pulmonary hyperinflation (TLC \> 120%). Patient that have signed inform consent.

Exclusion Criteria:

* Hospitalization within the previous 14 days
* Current participation in rehabilitation program,
* Locomotor or neurological condition or disability limiting the ability to perform exercise,
* Lung transplantation or lung volume reduction surgery foreseen within 1 month after discharge.
Phase II Study of Oral Nafithromycin in CABP

Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults


Eligibility Criteria:
Inclusion Criteria:

Meet the clinical criteria for CABP based on following:

1. Clinical symptoms (new or worsening)
2. Vital sign abnormalities
3. Laboratory abnormalities
4. Radiographic evidence of CABP
5. PORT score

Exclusion Criteria:

1. Subjects with any of the following confirmed or suspected types of pneumonia:

   1. Aspiration pneumonia
   2. Hospital-acquired bacterial pneumonia (HABP)
   3. Healthcare-associated bacterial pneumonia (HCAP)
   4. Ventilator-associated bacterial pneumonia (VABP)
   5. Pneumonia that may be caused by pathogen(s) resistant to either study drug
2. Receipt of 1 or more dose(s) of a potentially effective systemic antibacterial treatment for treatment of the current CABP
3. Suspected or confirmed non-infectious causes of pulmonary infiltrates
4. Subjects requiring concomitant adjunctive or additional potentially-effective systemic antibacterial treatment for management of CABP
A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

This study will assess if corifollitropin alfa (MK-8962), when administered in combination with human chorionic gonadotropin (hCG), will increase testicular volume in men with HH who remain azoospermic after treatment with hCG alone.

Hypothesis: The lower limit of the 95% confidence interval for the geometric mean increase in testicular volume from Day 1 to Week 52 is greater than one.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with hypogonadotropic hypogonadism, either congenital or acquired
* Have low circulating levels of testosterone
* Have low circulating levels of gonadotropins (follicle stimulating hormone \[FSH\]; luteinizing hormone)
* Presence of both scrotal testes
* Have azoospermia (no measurable level of sperm)
* Adequate replacement of other pituitary hormones
* Good general physical and mental health

Exclusion Criteria:

* Primary hypogonadism, such as Klinefelter's syndrome
* History of unilateral or bilateral cryptorchidism (maldescended testes)
* History or presence of testicular pathology of clinical importance (e.g., epididymitis, orchitis, testicular torsion, varicocele stage III, testicular atrophy, occlusive azoospermia, etc), and/or vasectomy
* Treated with FSH, hCG or gonadotropin-releasing hormone (GnRH) within previous 3 months or for more than 1 month within previous 6 months
* Proven spermatogenesis with hCG treatment alone
* Previous unsuccessful attempt with hCG in combination with human menopausal gonadotropin (hMG)/FSH to achieve spermatogenesis
* Required a dose of hCG of more than 6000 international units (IU) per week in a previous attempt to normalize T levels
* Untreated pituitary or hypothalamic tumor, or inadequately treated pituitary or hypothalamic tumor that is likely to progress during the study
* History or presence (known or suspected) of testicular, prostatic or breast cancer
* Prostate pathology of clinical importance
* Past or present oncologic treatment (chemo/radiotherapy)
* Diabetes mellitus
* Clinically significant, untreated hyperprolactinaemia
* Uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
* Tested positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
* User of recreational or illicit drugs or has had a recent history (within the past year) of drug abuse or dependence, or increased alcohol consumption
* Allergy/sensitivity to gonadotropins or its/their excipients
* Has received within previous 1 month or plans to use: Hormonal preparations other than the study medication, drugs that are known to impair testicular function, agents known to affect sex hormone secretion and/or drugs that are known or suspected to be teratogenic
* Used any investigational drugs within three months or actively participating in another study
Food Frequency Questionnaire (FFQ) for Coronary Heart Disease (CHD) Patients

This study aims to evaluate the psychometric properties of a newly developed FFQ specified for northern Chinese CHD and their high risk patients (CHD-FFQ). The psychometric properties include test-retest reliability, content validity, convergent validity, discriminant validity, concurrent validity and predictive validity. Particularly, this study will measure the physiological indicators, including plasma lipid profile (i.e. TG, TC, HDL-C, LDL-C), BG, BP and BMI twice at baseline and the end. The level of these physiological indicators will be compared with the fat intake measured by the CHD-FFQ, i.e. the baseline intake to test its convergent validity. It is also expected to predict the diet-related progression of CHD risks among high-risk individuals, i.e. patients with two or more CHD risk factors as following: raised fasting blood glucose (BG) level, increased blood pressure (BP), increased triglycerides (TG), decreased HDL-Cholesterol (HDL-C), increased LDL-Cholesterol (LDL-C), smoking and central obesity (International Diabetes Federation, 2015). In addition, this study will provide the FFQ's concurrent validity in assessing the intake of energy and nutrients against the CDC-FFQ. Moreover, whether the FFQ could detect the known differences in energy intake between men and women will be established for its discriminant validity.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older;
* Have no CHD at enrollment;
* At high risk of CHD with at least two of the following risk factors:

  * current smoking: current smokers are defined as individuals who smoked regularly during the last 12 months
  * central obesity: for Chinese, central obesity is defined as waist circumstance above 90cm for male and 80cm for female, or with BMI above 30kg/m²
  * raised BP (systolic BP \[SBP\] ≥ 130 mmHg or diastolic BP \[DBP\] ≥85 mmHg or under antihypertensive treatment)
  * raised fasting BG (FBG) (100mg/dL \[5.6mmol/L\]) or under treatment with insulin or oral hypoglycemic agents
  * elevated TG (150mg/dL \[1.7mmol/L\])
  * elevated TC (≥ 240 mg/dL \[5.18 mmol/L\])
  * raised LDL-C (≥ 160 mg/dL \[4.15 mmol/L\])
  * decreased HDL-C (\<40 mg/dL \[1.03 mmol/L\] for males, and \<50 mg/dL \[1.29 mmol/L\] for females)
  * undergoing hyperlipidemia treatment

Exclusion Criteria:

* Impaired bilateral hearing
* Impaired mental status (according to their medical record)
Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

The purpose of the study is to assess the effect of PF-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.


Eligibility Criteria:
Inclusion Criteria:

* Subject meets the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of acute Arthritis of Primary Gout.
* Subjects taking urate lowering therapy at the time of screening must be willing to discontinue their prior urate lowering therapy from the time of Screening Visit 1 until completion of the study period Day 16.
* Subjects taking urate lowering therapy at the time of screening must have a serum urate level of \>= 8.0 mg/dL at time of the second screening visit.
* Subjects NOT taking urate lowering therapy at the time of screening must have a serum urate level of \>= 8.0 mg/dL at both screening visits 1 and 2.

Exclusion Criteria:

* Positive medical history or current evidence of medical or psychiatric condition/disease, or ECG or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
* Chronic kidney disease classified as moderate or severe (Clinical Practice Guideline, National Kidney Foundation)12; with GFR \< 60 mL/min/1.73m2 calculated by the Cockcroft-Gault equation.
* Subjects with current tophaceous gout.
* Gout flare that has not resolved for at least 2 weeks prior to randomization.
Sternomental Displacement Test for Predicting Difficult Airway in Obese Patients

Difficulties airway significantly contribute to the morbidity and mortality associated with anesthesia. Identifying situations and patients at risk for airway management problems is the key to optimal care and has been the focus of numerous publications. Although controversial, Body Mass Index (BMI) is considered as associated with difficult intubation in both and operating theaters. A modified measurement of SMD is obtained with the head in neutral position (SMD neutral), then the difference between SMD extension and SMD neutral was calculated and it was referred to as sternomental displacement (SMDD). SMDD was proved to be a good objective predictor for difficult laryngoscopy in adult patients, and its predictive ability was increased when combined with other tests as neck circumference (NC). To the best of our knowledge, the validity of the SMDD test was not previously assessed in obese patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients of either sex, aged between 18-60 years old, ASA physical status II \& III with BMI \> 30 Kg/m2 undergoing elective surgical procedures under general anesthesia using endotracheal intubation by conventional laryngoscopy.

Exclusion Criteria:

* neuromuscular disorders, craniofacial abnormalities, abnormal dentition, lesions or scares in head and neck limiting the neck mobility, uncooperative, who needed awake intubation and patients who underwent emergency operations
Migraine in Electrohypersensitive Patients

The investigators propose here by the use of the French version of the migraine disease screening questionnaire (ID Migraine ™) to study the prevalence of migraine disease in a population of electrohypersensitive patients


Eligibility Criteria:
Inclusion criteria:

* Informed Consent
* 18 years or older at the time of informed consent

With all these criteria :

* the perception by the subjects of various non-specific functional symptoms
* the absence of clinical and biological evidence to explain the symptoms
* the attribution by the subjects themselves of these symptoms to exposure to electromagnetic fields, which are themselves diverse
* the symptoms are chronic (more than 3 months)
* the symptoms appear during an exposure to a source of electromagnetic radiation and cease after the exposure is stopped
* the symptoms are reproducible

Exclusion criteria:

- age under 18 years old
A Prospective, Open-label, Multi-center Pilot Study to Evaluate the Safety, Feasibility and Usability of the IDA

This is a multi-center, open label, cross-over clinical study. A total of 15 subjects will be enrolled to use the IDA for every peritoneal dialysis exchange for 14 days. To participate in the study, the subjects must have current CKD5 and have been treated with PD for at least 3 months. The subjects will undergo a single peritoneal dialysis exchange procedure at the PD clinic, under supervision of the medical staff and instructed about its operation. Further exchanges will be performed by the subjects themselves at home.

The study includes three periods:

First period (Observational): 14-day Observational Period. Eligible subjects who sign informed consent will continue with their regular CAPD treatment while performing measurement and recording of dialysate in/out time.

Second period (Interventional): 14-day interventional period, where subjects will perform dialysis exchanges using the IDA according to the below visit schedule.

Third period (Follow up): 14-day follow up period, during which the study staff will call the subject once weekly to inquire about device-related SAEs and any changes to concomitant medications.


Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects with CKD stage 5 under peritoneal dialysis
* Age ≥18 years
* Mental ability to understand the study procedures and provide informed consent
* At least 3 months on peritoneal dialysis prior to enrollment
* At least 3 daily exchanges
* Stable PD prescription for the last 2 months
* Subject who is self-treated

Exclusion Criteria:

* Need of cycler (APD)
* Known Mechanical problem during the last month (i.e. drainage or fill problems)
* Pregnant or breastfeeding women, and women with childbearing potential who is unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the entire clinical trial period.
* Subjects who are unwilling or unable to comply with study procedures
* Known Peritonitis or other catheter related infection during the last 3 months prior to enrollment
* Known Congestive Heart Failure stage III-IV
* Any history of kidney malignancy
* Any planned hospitalization for elective Procedure(s)throughout the duration of participation in the study
* Non-elective hospitalization in the last 3 months prior to enrollment
* Any other medical or mental condition, that at the investigator's discretion may prevent the subject from participating in the study
* Participation in any other clinical study within 4 weeks prior to enrollment
Diagnosis et Treatment of Asthma in Athlete : Boundary Between Disease and Doping

This study will determine the pharmacokinetic profile of the salbutamol concentration in the urine while athletes are resting or during exercise.


Eligibility Criteria:
Inclusion Criteria:

* patient who hold a license in a sport federation, and do at least 8 hours of sport each week
* asthmatic patient

Exclusion Criteria:

-